RxDoctor Payments Data

Dena Snead, DO

Internal Medicine · Candler, NCNPI 1154715936

Payments from drug & device makers

$751in general payments, 2019–2025

Across 22 payments — averaging $34.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$212
  • Boston Scientific$169
  • AstraZeneca$107
  • Lilly USA, LLC$58
  • AbbVie$55
  • Neurocrine Biosciences, Inc.$44
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$74098%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$751 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$53,671
Medicare patients
186
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$116,440
OzempicSemaglutide40$49,954
EliquisApixaban65$48,117
XareltoRivaroxaban25$30,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,572
TrulicityDulaglutide17$21,882
ViberziEluxadoline12$18,085
JardianceEmpagliflozin17$15,749
MyrbetriqMirabegron13$12,492
OxycontinOxycodone Hcl12$6,773
SymbicortBudesonide/Formoterol Fumarate17$3,704
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$3,428
Albuterol Sulfate HfaAlbuterol Sulfate80$2,420
Levothyroxine Sodium214$2,347
Omeprazole179$2,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$58$139,029108 claims
Novo NordiskOzempic, Levemir$212$51,09051 claims
PfizerEliquis$38$48,11765 claims
AbbVieViberzi$55$18,08512 claims
AstraZenecaSymbicort$107$3,70417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Candler

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →